Investigational Site Number 826001

London WC1N 3JZ

0 studies enrolling now · 6 studies all time

What they study most

Hematopoietic Neoplasm, Idiopathic Pulmonary Fibrosis, Sphingomyelin Lipidosis, Systemic Sclerosis, Venous Thromboembolism

Studies at this site

• Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib — Stopped early
• Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis — Completed
• A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency — Completed
• Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis — Completed
• Proof of Biological Activity of SAR100842 in Systemic Sclerosis — Completed
• Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery — Completed